Advertisement
GH vs RGEN
Which Stock Would AI Choose? Guardant Health (GH) vs. Repligen (RGEN) Stock Comparison
Key Takeaways
- Guardant Health (GH) has delivered explosive revenue growth exceeding 30% year-over-year, driven by its oncology testing and Shield blood-based colorectal cancer screening platform, but remains unprofitable on a GAAP (Generally Accepted Accounting Principles) basis.
- Repligen (RGEN) is a profitable, cash-flow-positive bioprocessing technology company with mid-teens organic revenue growth, supported by eight consecutive quarters of orders exceeding non-COVID revenue.
- Over the past twelve months, GH shares have surged more than 220%, while RGEN has posted a more modest single-digit gain, reflecting starkly different market sentiment and risk-reward profiles.
- GH carries significantly higher volatility (beta of 1.59) compared to RGEN (beta of 1.06), making the former more sensitive to market swings and sentiment shifts.
- Both stocks face upcoming earnings reports in late July 2026, which could serve as near-term catalysts for either confirming or challenging prevailing trends.
- The comparison highlights a core trade-off: high-growth, high-uncertainty diagnostics innovation versus steady, diversified bioprocessing supply with demonstrated profitability.
Introduction
Comparing GH and RGEN offers a window into two distinct value propositions within the healthcare and life sciences universe. Guardant Health is a precision oncology company at the forefront of liquid biopsy technology, while Repligen is a leading provider of bioprocessing tools and consumables that enable biologic drug manufacturing. Though both operate under the broad healthcare umbrella, their business models, growth trajectories, and risk characteristics diverge sharply. This stock comparison is particularly relevant for investors seeking to understand how innovation-driven diagnostics companies stack up against essential picks-and-shovels life sciences suppliers in the current market environment — and which one might better align with a given risk tolerance and time horizon.
GH Overview and Recent Performance
Guardant Health (NASDAQ: GH), headquartered in Palo Alto, California, has cemented its reputation as a pioneer in precision oncology and liquid biopsy — a technology that detects cancer-specific genetic mutations from a simple blood draw. The company's flagship Guardant360 test and its newer Shield blood-based colorectal cancer screening platform have driven accelerating revenue growth over recent quarters. In full-year 2025, Guardant Health reported total revenue of approximately $981 million, representing 33% year-over-year growth, with oncology test volumes climbing 34%. The company has guided for approximately $1.27 billion in revenue for 2026, reflecting continued confidence across its oncology, screening, and biopharma data businesses.
Shield has emerged as a significant growth catalyst, with nearly 100,000 patients screened since FDA (Food and Drug Administration) approval and inclusion in updated NCCN (National Comprehensive Cancer Network) colorectal cancer screening guidelines. The Shield Multi-Cancer Detection test also received FDA Breakthrough Device Designation, further expanding the addressable market. Despite these advances, Guardant Health continues to operate at a GAAP net loss, and free cash flow remains negative as the company invests aggressively in commercial infrastructure. In recent weeks, GH shares have traded in the $145–$170 range, reflecting both the bullish growth narrative and occasional bouts of profit-taking after a meteoric rise of more than 220% over the past year.
RGEN Overview and Recent Performance
Repligen Corporation (NASDAQ: RGEN), based in Waltham, Massachusetts, is a life sciences company that develops and commercializes bioprocessing technologies used in the production of biologic drugs. Its product portfolio spans filtration systems, chromatography columns, process analytics instruments, and proteins — all critical components in the manufacturing workflows of biopharmaceutical companies and CDMOs (Contract Development and Manufacturing Organizations). Repligen's business benefits from the secular growth of biologics and the trend toward more efficient, data-driven manufacturing.
In its most recent fiscal year, Repligen generated revenue of approximately $738 million, reflecting organic non-COVID growth in the mid-teens. The company has distinguished itself with consistent order momentum: as of its latest quarterly report, orders had grown over 20% year-over-year, marking the eighth consecutive quarter in which orders exceeded non-COVID revenue. Unlike Guardant Health, Repligen is profitable, posting GAAP net income and an adjusted EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) margin near 18%. In recent weeks, RGEN shares have pulled back from their 52-week highs and are trading around the $130–$140 level, weighed down by broader concerns around bioprocessing demand cycles and sector-wide project delays flagged by industry peers. Nonetheless, the company's diversified customer base and consumables-heavy revenue stream provide a degree of resilience.
Trending AI Robots
In a market environment increasingly shaped by volatility and rapid sector rotation, traders are turning to AI-driven tools for a data-backed edge. Tickeron's Trending AI Robots page showcases a curated selection of the platform's top-performing AI trading bots — handpicked from hundreds of available bots that collectively trade thousands of different tickers. These featured bots represent those best suited to current market conditions, with some posting annualized returns exceeding 70%, win rates above 65%, and profit factors surpassing 4.0 — meaning over $4 earned for every $1 risked. Each bot operates with its own trading style, strategy, timeframe, and ticker universe, ranging from 5-minute and 15-minute high-frequency agents to 60-minute swing-trading models. For investors and traders looking to supplement their own analysis with AI-powered signals, exploring the Trending AI Robots section is a practical next step.
Head-to-Head Comparison
The contrast between GH and RGEN is most pronounced when examining business models and growth profiles. Guardant Health operates in the diagnostics sector, where reimbursement dynamics, FDA clearances, and guideline inclusions directly influence revenue ramp and market penetration. Its revenue growth has been exceptional — north of 30% — but the company remains deeply unprofitable as it invests in scaling its Shield screening franchise. Repligen, by contrast, operates an essential supplier model: its filtration, chromatography, and analytics products are embedded in the manufacturing processes of biologic drugs, generating recurring consumable revenue. Growth is steadier at 12–16% organically, but the company is already profitable and generating positive operating income.
Market sentiment toward the two stocks has diverged meaningfully. GH has rewarded shareholders with triple-digit percentage gains over the past year, as optimism around Shield adoption and oncology test volume acceleration has driven multiple expansion. RGEN, despite delivering consistent order growth and profitability, has seen its stock underperform year-to-date, weighed down by macroeconomic uncertainty around biotech funding and cautious bioprocessing demand signals. Sector exposure also differs: GH is tied to cancer screening volumes, Medicare reimbursement policy, and diagnostic guideline decisions, while RGEN's fortunes are linked to biopharma capital expenditure cycles, biologic drug pipelines, and CDMO capacity utilization.
Risk factors further separate the two. GH's high beta of 1.59 signals greater sensitivity to market-wide swings and a more sentiment-driven trading pattern, while RGEN's beta of 1.06 suggests it moves more closely in line with the broader market. GH's path to sustained profitability hinges on execution in the Shield commercial rollout and eventual free cash flow breakeven, while RGEN faces headwinds from new modality demand softness and potential tariff-related margin pressure.
Tickeron AI Verdict
Based on observable market data — including trend consistency, relative momentum, and sector positioning — Tickeron's AI models would likely favor GH in the current environment for trend-following strategies, given its stronger price momentum, accelerating revenue growth, and the sustained expansion of its total addressable market through Shield. However, for risk-adjusted, mean-reversion, or fundamentally weighted strategies, RGEN would likely appear more attractive due to its established profitability, lower volatility, and demonstrated order-book resilience. The AI-driven preference ultimately depends on the specific strategy employed: trend and momentum signals lean toward GH, while stability and valuation-conscious models tilt toward RGEN. Neither outcome represents a definitive forecast — only a probabilistic assessment shaped by real-time data and market structure.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is GH is a Buy and RGEN is a Hold.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
GH’s FA Score shows that 0 FA rating(s) are green whileRGEN’s FA Score has 0 green FA rating(s).
- GH’s FA Score: 0 green, 5 red.
- RGEN’s FA Score: 0 green, 5 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
GH’s TA Score shows that 4 TA indicator(s) are bullish while RGEN’s TA Score has 4 bullish TA indicator(s).
- GH’s TA Score: 4 bullish, 4 bearish.
- RGEN’s TA Score: 4 bullish, 4 bearish.
Price Growth
GH (@Medical Specialties) experienced а +9.95% price change this week, while RGEN (@Pharmaceuticals: Other) price change was +6.86% for the same time period.
The average weekly price growth across all stocks in the @Medical Specialties industry was +0.40%. For the same industry, the average monthly price growth was -3.39%, and the average quarterly price growth was +6.80%.
The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was +5.03%. For the same industry, the average monthly price growth was +0.09%, and the average quarterly price growth was -1.71%.
Reported Earning Dates
GH is expected to report earnings on Oct 29, 2026.
RGEN is expected to report earnings on Nov 03, 2026.
Industries' Descriptions
@Medical Specialties (+0.40% weekly)Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.
@Pharmaceuticals: Other (+5.03% weekly)Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.
| GH | RGEN | GH / RGEN | |
| Capitalization | 21.7B | 7.96B | 273% |
| EBITDA | -411.19M | 172M | -239% |
| Gain YTD | 58.596 | -13.945 | -420% |
| P/E Ratio | N/A | 193.16 | - |
| Revenue | 1.18B | 785M | 151% |
| Total Cash | 1.05B | 810M | 130% |
| Total Debt | 1.7B | 691M | 246% |
GH | RGEN | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 82 | 50 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 65 Fair valued | 82 Overvalued | |
PROFIT vs RISK RATING 1..100 | 79 | 100 | |
SMR RATING 1..100 | 100 | 90 | |
PRICE GROWTH RATING 1..100 | 34 | 46 | |
P/E GROWTH RATING 1..100 | 100 | 100 | |
SEASONALITY SCORE 1..100 | n/a | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
GH's Valuation (65) in the Medical Or Nursing Services industry is in the same range as RGEN (82) in the Biotechnology industry. This means that GH’s stock grew similarly to RGEN’s over the last 12 months.
GH's Profit vs Risk Rating (79) in the Medical Or Nursing Services industry is in the same range as RGEN (100) in the Biotechnology industry. This means that GH’s stock grew similarly to RGEN’s over the last 12 months.
RGEN's SMR Rating (90) in the Biotechnology industry is in the same range as GH (100) in the Medical Or Nursing Services industry. This means that RGEN’s stock grew similarly to GH’s over the last 12 months.
GH's Price Growth Rating (34) in the Medical Or Nursing Services industry is in the same range as RGEN (46) in the Biotechnology industry. This means that GH’s stock grew similarly to RGEN’s over the last 12 months.
GH's P/E Growth Rating (100) in the Medical Or Nursing Services industry is in the same range as RGEN (100) in the Biotechnology industry. This means that GH’s stock grew similarly to RGEN’s over the last 12 months.
| GH | RGEN | |
|---|---|---|
| RSI ODDS (%) | 3 days ago 81% | 4 days ago 67% |
| Stochastic ODDS (%) | 3 days ago 87% | 3 days ago 72% |
| Momentum ODDS (%) | 3 days ago 85% | 3 days ago 75% |
| MACD ODDS (%) | 3 days ago 73% | 3 days ago 82% |
| TrendWeek ODDS (%) | 3 days ago 80% | 3 days ago 72% |
| TrendMonth ODDS (%) | 3 days ago 82% | 3 days ago 71% |
| Advances ODDS (%) | 3 days ago 82% | 18 days ago 74% |
| Declines ODDS (%) | 6 days ago 85% | 7 days ago 81% |
| BollingerBands ODDS (%) | 3 days ago 79% | 3 days ago 85% |
| Aroon ODDS (%) | 3 days ago 86% | 3 days ago 77% |
Advertisement
GH and
Correlation & Price change
A.I.dvisor indicates that over the last year, GH has been loosely correlated with NTRA. These tickers have moved in lockstep 50% of the time. This A.I.-generated data suggests there is some statistical probability that if GH jumps, then NTRA could also see price increases.
RGEN and
Correlation & Price change
A.I.dvisor indicates that over the last year, RGEN has been closely correlated with DHR. These tickers have moved in lockstep 67% of the time. This A.I.-generated data suggests there is a high statistical probability that if RGEN jumps, then DHR could also see price increases.
| Ticker / NAME | Correlation To RGEN | 1D Price Change % | ||
|---|---|---|---|---|
| RGEN | 100% | -1.80% | ||
| DHR - RGEN | 67% Closely correlated | -0.61% | ||
| A - RGEN | 65% Loosely correlated | -0.25% | ||
| BIO - RGEN | 60% Loosely correlated | -0.38% | ||
| MTD - RGEN | 59% Loosely correlated | +2.59% | ||
| TMO - RGEN | 58% Loosely correlated | -0.43% | ||
More | ||||